Surge in demand turns Wegovy pill into high-stakes commodity amid shortages.

A surge in demand has transformed the Wegovy pill into a high-stakes commodity, with reports indicating that patients are now ordering the oral tablet at a rate ten times higher than the injectable version. This dramatic shift underscores a critical bottleneck in the current healthcare landscape: the widespread availability of the pill is being stifled by severe shortages and protracted waiting lists.

Federal regulatory frameworks and manufacturer supply chain constraints are directly impacting patient access, creating a situation where those most in need face the longest delays. As companies struggle to meet the exploding demand, the gap between clinical necessity and actual availability is widening, forcing clinicians to navigate a complex landscape of restricted inventory.

The urgency of this issue cannot be overstated. With thousands of individuals waiting for weight-loss medication that was once widely prescribed, the current system appears ill-equipped to handle the volume of requests. Stakeholders warn that without immediate intervention to streamline distribution and expand production capacity, the backlog will only grow, leaving vulnerable populations without timely treatment.

The newly approved oral Wegovy pill has ignited a surge in demand, with early indicators suggesting it may surpass the popularity of its injectable counterpart. This breakthrough tablet, an oral version of the once-weekly Wegovy injection, has driven patients to queue up for prescriptions immediately. Simple Online Healthcare reported receiving more than ten times the number of orders on its first day compared to the launch of the Mounjaro injection in the UK in 2024.

Currently, the medication, capable of helping users lose up to 17 per cent of their body weight, is expected to be dispensed exclusively through private providers. These outlets include high street retailers such as Morrisons, Superdrug, and Boots, as well as an expanding array of online pharmacies. While prices have not been officially confirmed, some pharmacists estimate the cost could start at around £99 per month, potentially undercutting the injectable versions. If supply chains hold, the company anticipates the first prescriptions will be fulfilled as early as July.

However, a critical question looms: will supplies last? With tens of thousands of patients already on waiting lists, experts warn that availability may fail to keep pace with the exploding interest. Simple Online Healthcare noted its waiting list had already swelled to approximately 60,000 patients even before the drug received approval for obesity treatment in the UK. Similarly, online retailer Chemist4U reports a waiting list exceeding 10,000 customers.

Early data suggests the pill is attracting a distinct demographic compared to injectable weight-loss drugs. According to Simple Online Healthcare, older adults and men—groups historically less likely to utilize weight-loss medication—are appearing more frequently among new sign-ups. Adults in their 60s now account for around 20 per cent of pill pre-orders, compared to 13 per cent of injection users, while those in their 50s represent the largest share overall at 35 per cent. Men comprise roughly a quarter of pill users, up from about one in five among injection users.

Abdal Alvi, chief clinical officer at Simple Online Healthcare, stated that these early findings indicate the tablet could finally reach patients who previously avoided injections. "The people coming forward in the greatest numbers are those injectable treatment was least likely to reach," he remarked. This shift is particularly significant given that obesity rates are highest among older age groups; NHS data shows around one in three people aged 55 to 74 are obese, yet this demographic has historically been reluctant to seek pharmaceutical intervention. Men have similarly lagged in accessing treatment despite high obesity levels, with studies suggesting uptake remains significantly lower than among women.

The introduction of an oral alternative is poised to broaden access and increase overall demand. Leveraging early data alongside US trends, Simple Online Healthcare estimates that between 120,000 and 130,000 patients could begin using oral GLP-1 treatments within the first few months of launch. The company projects that around 100,000 of these users would likely be new patients rather than individuals switching from injections.

Nevertheless, these projections remain preliminary, and national demand patterns are not yet fully understood. Previous weight-loss drugs, including injectable Wegovy and Mounjaro, have suffered repeated supply shortages as demand outstripped availability, raising fears that the same could happen again. At least 1.6 million adults in the UK are currently using weight-loss injections, with a further 3.3 million considering them. Polling by digital healthcare provider Numan found that approximately one in five people considering medication are deterred by a fear of needles. Now that a simpler oral tablet is approved, experts believe demand will soar because it offers an option to avoid self-injection.

This anticipated surge could trigger severe supply issues. Prof David Strain, an obesity expert at the University of Exeter, explained the manufacturing implications: "The pills contain around 100 times as much of the active drug as the injections, because a lot of it gets absorbed in the gut." Consequently, the drug company will be forced to produce far more of the active ingredient than before, creating a race against time to meet the urgent needs of a waiting public.

Recent years have seen severe shortages of weight-loss injections due to surging demand. Experts warn that a similar rush for Wegovy pills could trigger new supply crises. A spokesperson for Novo Nordisk addressed The Daily Mail last week. The company stated it remains confident that sufficient pill supplies exist. However, the threat of scarcity looms if public demand spikes unexpectedly.